← All trials
NCT06312982
Phase 2/Phase 3Interventional
Trials that are a combination of phases 2 and 3.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Feb 20, 2024
- Primary completion
- Dec 31, 2026
- Completion date
- Dec 31, 2026
- First posted
- Mar 15, 2024
- Last posted
- Mar 15, 2024
- Enrollment
- 375
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Capital Medical UniversityLead sponsor
- Sichuan UniversityCollaborator
- Zhejiang UniversityCollaborator
- China Medical UniversityCollaborator
- Jinlin UniversityCollaborator
- Peking UniversityCollaborator
- Shandong Provincial HospitalCollaborator
- Anhui Medical UniversityCollaborator
- People's Liberation Army of ChinaCollaborator
- Capital Medical UniversitySponsor investigator
- Xiamen UniversityCollaborator
- Chinese Academy of Medical SciencesCollaborator
- Chinese Academy of Medical SciencesCollaborator
- Zhengzhou UniversityCollaborator
- Jiao Tong UniversityCollaborator
- Sun Yat-Sen UniversityCollaborator
- Capital Medical UniversityCollaborator
- Changhai HospitalCollaborator
- Fudan UniversityCollaborator
- Qingdao UniversityCollaborator
- Tianjin Medical UniversityCollaborator
- China Ministry of HealthCollaborator
- The University of Hong KongCollaborator
- Shanxi Medical UniversityCollaborator
- The University of Hong KongCollaborator
- Hebei UniversityCollaborator
- Southern Medical UniversityCollaborator
- Chongqing Medical UniversityCollaborator
- Tianjin UniversityCollaborator
- Wenzhou Medical UniversityCollaborator
- Air Force Military Medical University, ChinaCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.